Epidermal growth factor receptor tyrosine kinase inhibitors

Current Opinion in Pharmacology

Volumn 2, Issue 4, 2002, Pages 382-387

  Wakeling, Alan E ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; ONCOPROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; PYRROLO[2,3 D]PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMOPROPHYLAXIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; HORMONAL THERAPY; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTO ONCOGENE; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG COMBINATION; ENZYMOLOGY; METABOLISM; NEOPLASM; REVIEW;

ANIMALS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0036667387     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(02)00183-2     Document Type: Review

References (48)

1. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor
2. ZD1839 ('Iressa') as an anticancer agent
3. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
4. Initial results from a Phase II trial of ZD1839 ('Iressa') as second- and third-line monotherapy for patients with advanced non-small-cell lung cancer (IDEAL 1)
5. ECCO 11 welcomes EGFR-targeted anticancer agents
6. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
7. CI-1033, pan-erbB kinase inhibitor
8. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer
9. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo
10. Studies leading to the identification of ZD1839 (Iressa™): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
11. Antitumour effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
12. ZD1839 (IRESSA), a novel epidermal growth factor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without ERBB2 overexpression
13. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family
14. Efficacy of cytotoxic agents against human tumour xenografts is markedly enhanced by co-administration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
15. Tumour EGFR expression: Assessment and implications
16. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathalogic and molecular consequences of receptor inhibition
17. Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor α expression in head and neck squamous carcinoma and inhibition by anti-epidermal treatments
18. Epidermal growth factor receptor family and chemosensitization
19. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells
20. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex)
21. Combination therapy with ZD1839 ('Iressa'), an orally active, selective, epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin, in patients with advanced solid tumours: Promising on tolerability, efficacy and pharmacokinetics
22. ZD1839 ('IRESSA'), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced colorectal cancer
23. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 ('Iressa'), a selective epidermal growth factor receptor tyrosine kinase inhibitor
24. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor iressa causes cooperative antitumor and antiangiogenic activity
25. Combination of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor and radiotherapy increases antitumour efficacy in a human colon cancer xenograft model
26. Modulation of radiation response and tumor-induced angiogenesis following EGFR blockade by ZD1839 ('Iressa') in human squamous cell carcinomas
27. ZD1839 (Iressa) improves the antitumor activity of tamoxifen ('Nolvadex') in antihormone-responsive breast cancer cells
28. Studies with CWR22 xenograft models in nude mice suggest that ZD1839 ('Iressa') may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer
29. The erbB signalling network: Receptor heterodimerization in development and cancer
30. Untangling the erbB signalling network
31. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer
32. Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase
33. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
34. The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signalling and suppresses the growth of HER2-overexpressing tumor cells
35. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo
36. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo
37. Cooperative inhibitory effect of ZD1839 ('Iressa') in combination with trastuzumab (Herceptin) on human breast cancer cell growth
38. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation
39. Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2
40. Inhibition of HER2/neu (erbB2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells
41. Prospects for combining hormonal and nonhormonal growth factor inhibition
42. Cancer prevention by delay
43. Lung cancer prevention: Retinoids and the epidermal growth factor receptor - A phoenix rising?
44. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu+MMTV/TGF-α bigenic mice
45. Effect of epidermal growth factor receptor kinase inhibition on epithelial proliferation in normal and premalignant breast
46. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention
47. Combinatorial chemoprevention of intestinal neoplasia
48. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth